ABSTRACT: Adamantanyl benzamide 1 was identified as a potent, P2X7R antagonist but failed to progress further due to poor metabolic stability. We describe the synthesis and SAR of a series of bioisosteres of benzamide 1 to explore improvements in the pharmacological properties of this lead. Initial efforts investigated a series of heteroaromatic bioisosteres which demonstrated improved physicochemical properties but reduced P2X7R antagonism. Installation of bioisosteric fluorine on the adamantane bridgeheads was well tolerated and led to a series of bioisosteres with improved physicochemical properties and metabolic stability. Trifluorinated benzamide 34 demonstrated optimal physicochemical parameters, superior metabolic stability (ten times longer than lead benzamide 1), an improved physicokinetic profile and proved effective in the presence of several known P2X7R polymorphisms.
The P2X7 purinoreceptor (P2X7R) is a non-selective, ligand-gated cation channel ubiquitously expressed on many immune cells including microglial cells in the Central Nervous System (CNS). It is up-regulated in response to pro-inflammatory stimuli and has been implicated in a number of neuroinflammatory diseases. Activation of the P2X7R by the extracellular nucleotide adenosine triphosphate (ATP) mediates the processing and release of the pro-inflammatory cytokine, interleukin 1 (IL-1), which is involved in a variety of cellular actions, including cell proliferation, differentiation, and apoptosis. Additionally, pharmacological inhibition and genetic studies of the P2X7R have shown elimination or reduction of symptoms in animal models of arthritis, depression, neuropathic pain, multiple sclerosis, and Alzheimer's disease. 1 The modulation of P2X7R activity through the development of P2X7R antagonists appears to be a viable strategy for the treatment of neuroinflammatory diseases. Numerous drug classes have been identified in the pursuit to discover selective P2X7R antagonists.
2 Of this diverse library, only a handful have proceeded to clinical trials ( Figure 1) . 3 Of this list, all disclosed compounds belong to the carboxamide class of P2X7R antagonists whereby an aryl group is linked to a cycloalkyl group by *Undisclosed structures are speculative based on filed patents. a carboxamide linker. These compounds appear to be evolutionary from a series of potent carboxamides first reported by AstraZeneca 4 Unfortunately, these initial carboxamides (such as adamanatanyl benzamide 1) were reported to have low metabolic stability. Consequently, we and others have comprehensively explored the chemical space around AstraZeneca's adamantanyl benzamide series in the hope of improving the activity and ADMET properties of this series Several structure-activity relationships (SARs) studies have investigated altering the aryl substituents to explore or reduce the lipophilicity of these series resulting in leads such as AZD9056, CE-224,535, and speculatively AFC-5128.
3b, 3d Large molecular mass is a consequence of this strategy which could impede bioavailability and blood-brain penetration. The amide linker has been reversed, substituted and replaced (such as in GSK1482160) with no significant improvements reported. Early hit-to-lead studies have suggested that removing or flattening the adamantane to a simpler cycloalkane, to reduce lipophilicity and molecular weight, is detrimental to potency suggesting a large three-dimensional structure is central to potent P2X7R antagonism. 5 We, and others, 6 have confirmed this notion by substituting the adamantane of lead benzamide 1 with a variety of polycyclic cages (from cubane to carborane) and found that the larger polycyclic volume was crucial for P2X7R antagonism.
3c Unfortunately, the larger polycycles also result in more lipophilic compounds. In fact, most of the potent benzamide-based P2X7R antagonists reported in the literature all appear to suffer from high lipophilicity -a consequence of having an adamantane cage. We therefore sought to explore whether the original adamantanyl benzamide structures, identified as potent P2X7R antagonists albeit poor drug candidates due to high lipophilicity and poor metabolic stability, could be improved through bioisosteric strategies with the aim to develop a pre-clinical lead suitable for CNS studies. In this study, two common bioisosteric strategies were systematically explored -heteroaromatic replacement of the aryl ring and the fluorine-for-hydrogen substitution on the adamantane cage. These strategies were investigated through the synthesis and biological evaluation of a series of bioisosteres of adamantanyl benzamide 1. Adamantanyl benzamide 1 (hP2X7R pA2 8.8) was one of the lead benzamides identified in AstraZeneca's HTS and was the basis of our previous exploration on polycycle alternatives. 3c As such, this investigation would provide further systematic data to aid in the development of a P2X7R pharmacophore.
Furthermore, the methoxy group has the potential to be used as a site for radiolabeling in PET imaging studies as is the case for JNJ54173717 (Figure 1 ). 7 Our initial strategy looked at replacing the benzene ring with heteroaromatic rings, namely azabenzenes and diazines, which has shown to both reduce lipophilicity and improve metabolic stability in other applications. 8 Three regioisomers for the pyridine analogues of lead benzamide 1 are possible (Scheme 1). The orthopyridine 2 and para-pyridine 3 analogues (with respect to the carboxamide) were synthesized via the same synthetic sequence. In each case, the pyridinyl nitrogen of 3,6-dichloropicolinic acid 4 and 2,5-dichloroisonicotinic acid 5 was exploited to regioselectively direct aromatic nucleophilic substitution of the desired chloride with methoxide in excellent yields. Amide coupling with 3 adamantanylmethylamine 8 via in situ acid chloride formation generated the picolinamide 2 and isonicotina mide 3 analogues. The nicotinamide 9 analogue was synthesized from 2-chloro-5-hydroxynicotinic acid 10 which was alkylated to form ester 11, then saponified to nicotinic acid 12. Finally, amide coupling to adamantanylmethylamine 8 generated nicotinamide 9. To further explore the effect of heteroaromatic substitution on lead benzamide 1, the three possible diazine regioisomers were synthesized. The pyrimidine-4-carboxamide analogue 13 was prepared from 2,5-dichloropyrimidine 14, with the dual activation of the pyrimidine nitrogen atoms making the desired chloride substitution with methoxide regioselectively easy to generate pyrimidine 15. The ester functionality of 16 was then installed via a Minisci-type reaction which required strict control of reaction time to minimize over-reaction to the diester. 9 Saponification of ester 16 yielded the pyrimidinecarboxylic acid which was insoluble in most solvents, making amide coupling challenging. Consequently, direct aminolysis of ester 16 with adamantanemethylamine 8 was sufficient to generate pyrimidinamide-4-carboxamide 13 for testing. The pyridazinamide 17 was synthesized in an identical route from 3,6-dichloropyradazine 18 except the pyradazinecarboxylic acid 21 was synthetically useful in generating pyridazinamide 17. Unfortunately, the pyrazinamide analogue 22 could not be obtained from the same route. Several other synthetic means of obtaining the final diazine regioisomer 22 also proved unfruitful and so the synthesis of the pyrazinamide analogue 22 was stalled until the heteroaromatic analogues available in hand were assessed for biological activity. 
Compound
LogD7. 4 The lipophilicity of the azabenzamide series (Table 1) was evaluated by an experimentally-derived LogD7.4 value determined by a HPLC method. 10 All analogues, except for the 2-pyridinamide 2, were less lipophilic than lead benzamide 1. The azabenzamide series were then assessed in vitro for their ability to inhibit human P2X7R (hP2X7R) pore formation by using a functional dye uptake assay in THP-1 cells. 11 Unexpectedly, the entire azabenzamide series was less active than lead benzamide 1 (IC50 10.5 nM) with the isonicotinamide analogue 3 being the best of the series (IC50 63.1 nM). The addition of a second nitrogen into the ring to generate the diazine series (13 and 17) resulted in a further reduction of activity. The micromolar potency exhibited by these two diazines suggested that the planned pyrazinamide 22 was not likely worth exploring. The LigandLipophilicity Efficiency (LLE) calculated for each of the azabenzamide analogues were less than the lead benzamide 1 suggesting they are all less drug-like. 12 The drastic loss in P2X7R inhibition far surpassed any benefits gained by reducing the lipophilicity of lead benzamide 1 through this bioisosteric manipulation. Overall, it was observed that altering the electronics of the benzene ring of lead benzamide 1 through heteroaromatic substitution is detrimental to P2X7R inhibition and is not a viable bioisosteric strategy to apply to the benzamide P2X7R inhibitor series. Our second bioisosteric strategy investigated the introduction of fluorine-for-hydrogen substitution at the bridgehead carbons of the adamantane cage. The highly electronegative fluorine atom forms strong, polar covalent bonds with carbon that reduces lipophilicity and blocks metabolically-labile sites. Its small atomic radius mimics the hydrogen atom to ensure no steric bulk is added to the molecule. The synthesis of the fluorinated adamantane bioisosteres replicates the synthetic strategy reported by Pfizer involving a series of oxidation and deoxyfluorination steps. 13 To begin, methyl adamantanecarboxylate 23 was hydroxylated via a nitronium ion mediated hydride abstraction in nitric and sulfuric acid.
14 The subsequent hydroxyl-ester 24 was then subjected to deoxyfluorination to install the first bridgehead fluorine and then hydrolyzed to generate 3-fluoroadamantane-carboxylic acid 25 and is a divergent point of the synthesis. The 3-fluoroadamantanecarboxylic acid 25 can be converted to the 3-fluoroadamantanemethylamine 26 by amidation with ammonia then subsequent lithium aluminum hydride reduction of the carboxamide. The 3-fluoroadamantanemethylamine 26 is then coupled to the desired 2-chloro-5-methoxybenzoic acid 27 (Supporting information) with PyBOP to yield the monofluorinated benzamide analogue 28 in 73% yield. The procedure of oxidation (albeit with permanganate), deoxyfluorination and PyBOP coupling was repeated to obtain the 3,5-difluoro and 3,5,7-trifluoro analogs 33 and 34 respectively. A single crystal X-ray structure of trifluorinated benzamide 34 was successfully obtained (S information) which confirms the three fluorine atoms on the bridgehead carbons of adamantane and also illustrates the ortho chlorine atom sterically forcing the benzamide amide bond to twist out of plane with the benzene ring (ϕ Indeed, the synthesis to install fluorine-for-hydrogen substitution on the adamantane cage proved to be valuable with the HPLC-determined LogD7.4 values (Table 2) for all fluorinated analogues reported to be less than the lead benzamide 1 and the azabenzamide series ( Table  1 ). The fluorinated benzamides 28, 33, and 34 still displayed nanomolar activity in the hP2X7R functional assay and other in vitro assays. Only a small reduction in activity resulted from the installation of the fluorine atoms suggesting the fluorine-for-hydrogen substitution on the adamantane cage is tolerated. With reduced lipophilicity and comparable P2X7R activity relative to the lead benzamide 1, these fluorinated benzamides exhibited much higher LLE values than the lead benzamide 1 suggesting they may be improved drug candidates. A molecular hybrid of the two bioisosteric studies was also synthesized to validate the trends observed in both these studies. The 3,5-difluoro isonicotinamide 39 was synthesized from the amide coupling of 3,5-difluoroadamantanemethylamine 32 and 5-chloro-2-methoxyisonicotinic acid 7. The isonicotinic acid 7 was a IC50 values were the mean values (n >4) ± standard deviation derived from a dye uptake assay with THP-1 cells. b IC50 values were the mean values (n > 3) ± standard deviation derived from calcium influx in HEK cells expressing hP2X7R or mP2X7R.
c Binding affinities (Ki) were the mean values (n > 3) ± standard deviation derived from the displacement of tritiumlabeled benzamide 1-t3 in HEK cells expressing hP2X7R.
d LLE = pIC50 (from dye uptake) -LogD (from HPLC). Details of all assay conditions are provided in the Supporting Information. selected for the study as its azabenzamide resulted in the highest activity (IC50 63 nM) of the azabenzamide series. The two bioisosteric strategies had a synergistic effect on lipophilicity with the hybrid benzamide 39 possessing the lowest lipophilicity of our entire library (LogD7.4 2.82). Unfortunately, the loss in hP2X7R activity of each bioisostere also appeared to coalesce to produce a molecular hybrid with less activity (IC50 234 nM) than each of the individual bioisosteres 33 (IC50 30.9 nM) and 3 (IC50 63 nM) and much less than the lead benzamide 1 (IC50 10.5 nM). Based on these results, fluorinated benzamides 28, 33, and 34 were progressed further. The hP2X7R inhibition activity of the lead benzamide 1 and fluorinated benzamides 28, 33, and 34 were evaluated further by a calcium influx assay (Table 2) . In this assay, all the fluorinated benzamides exhibited a greater inhibitory effect (IC50 10-25 nM) than in the dye uptake assay (IC50 25-34 nM). In addition, these results were equal to or better than the lead benzamide 1 (IC50 26 nM) . Interestingly, the activity of the lead benzamide 1 and all three fluorinated analogues 28, 33, and 34 in the mP2X7R calcium flux assay was particularly poor. Whilst all benzamides perform equally well on the hP2X7R, there appears to be a trend with the mP2X7R favoring the more fluorinated benzamides. The reduced activity of the benzamides on the mP2X7R was not unexpected given the adamantanyl benzamide series are allosteric inhibitors and so likely possess poor interspecies crossover. 15 Nevertheless, the trifluorobenzamide 34 only exhibits a 6-fold drop in activity against the mP2X7R, compared to a 74-fold drop for the desfluorobenzamide 1, and so may be a useful probe in evaluating the role of the P2X7R in mouse disease models. The tritium radiolabeled parent benzamide (1-t3) was used to examine the binding affinities of the fluorinated benzamide analogues on membranes from human P2X7R HEK-transfected cells (Table 2 ). All fluorinated benzamides exhibited comparative binding affinities (22-32 nM) to the parent benzamide (8.5 nM). There was a slight drop in affinity with the addition of each fluorine atom to the adamantane cage suggesting the adamantane cage plays a critical role in binding to a hydrophobic pocket which is subtly disrupted, yet tolerated, with the addition of each electronegative fluorine atom. With the fluorinated bioisosteres 28, 33 and 34 demonstrating improved drug-like properties over lead benzamide 1 in pharmacological studies, they were progressed to in vitro drug metabolism studies (Table 3) . None of the fluorinated benzamides were identified as potential P-gp substrates in apparent permeability studies with all compounds exhibiting similar efflux ratios. This is a promising result given that AZD9056, a closelyrelated adamantane benzamide that failed in phase IIb clinical trials, is reported as being a P-gp substrate. 16 In rat liver microsome (RLM) stability studies, the addition at least 2 fluorine atoms to the adamantane cage was required to note any improvement in compound halflife. The trifluorobenzamide 34 exhibited the greatest stability with a half-life 6 times longer than the lead benzamide 1. A similar trend is observed in the CYP profile studies whereby the fluorinated benzamides 28, 33 and 34 encountered less CYP enzyme interactions (with the exception of CP3A4) than the lead benzamide 1 with the trifluorinated benzamide 34 performing the best. Future studies will assess the extent of CYP3A4 inhibition at the lower concentrations envisaged for dosing. The oxidation of the bridgehead carbons of adamantane is a major metabolic pathway for adamantane 17 and we speculate that this is the likely fate for all conventional adamantanyl benzamide libraries which ultimately translates to poor pharmacokinetic results. Through the fluorination of the bridgehead carbons of the adamantane moiety, we have not only improved the physicochemical properties of lead benzamide 1, but also hindered the main metabolic pathway which has resulted in metabolically more stable compounds. Half-lives were calculated using the gradient derived from plotting compound stability against time with n=3 at each time point.
c Cytochrome P450 isozyme inhibition values were mean (n=3) ± SEM. Details of all assay conditions are provided in the Supporting Information.
One of the major challenges that this study seeks to address is to improve the pharmacokinetic profile of lead benzamide 1, which was reported to have poor bioavailability following oral administration. Whilst the mono and difluorinated benzamides 28 and 33 respectively, exhibited similar pharmacokinetics to the lead benzamide 1, the trifluorinated benzamide 34 displayed superior results (Table 4 ). All four compounds achieved equivalent maximum concentrations (Cmax 4-7 mM) in the brain that equated to over 100 times their binding affinity (Table 2) . However, all three fluorinated benzamides exhibited a higher percentage of unbound drug, in both plasma and brain, than lead benzamide 1. In the brain, the distribution of benzamides increases proportional to the amount of fluorine atoms present on adamantane with the volume of distribution (Vd) for trifluorobenzamide 34 determined to be 3 times greater than lead benzamide 1. Analyzing the elimination data, we observe that trifluorobenzamide 34 exhibits enhanced metabolic stability over all other benzamides of the series [consistent with our RLM results (Table 3) ], with a plasma and brain half-life (T1/2) of 3.7 and 7.9 (respectively) times longer than the lead benzamide 1. The improved metabolic stability of trifluoribenzamide 34 resulted in an improved drug exposure profile (AUC) which was almost twice that of all other benzamides in the series. In humans, the P2X7R is highly polymorphic with the current Build of the NCBI database (Build 141) reporting 299 amino acid altering mutations in hP2X7R, of which 11 have a minor allele frequency above 1% (defined as a single nucleotide polymorphism; SNP). Many studies are linking P2RX7R polymorphisms to various disease states. 18 It is therefore imperative that any potential drug lead also be effective against disease-inducing polymorphisms. We explored the inhibitory potency of our trifluorinated benzamide 34 lead against six functionally characterized hP2X7R SNPs which are known to cause either gain-of-function or no change in function of hP2X7R (Table 5 ). The trifluorinated benzamide 34 is well tolerated against these SNPs with little to no loss of inhibitory activity, suggesting a potential to modulate P2X7R activity in diseases states involving polymorphisms. a IC50 values were the mean values (n = 2-3 transfections) ± standard deviation derived from a dye uptake assay against ATP (1 mM) or BzATP (100 M) with HEK293 cells transiently transfected with plasmids of functional P2X7R SNP variants.
b Plasmid contains 348T and 460R.
We describe the synthesis, SAR and pharmacokinetic results of a series of azabenzamide and fluorinated adamantane bioisosteres of lead benzamide 1 in an effort to improve the lead's physicochemical and pharmacokinetic properties. Incorporation of one or two nitrogen atoms into the benzene ring, to generate the azabenzamide series, resulted in less lipophilic candidates but at the expense of significantly reduced inhibition values. Incorporation of fluorine at the bridgehead carbons of the adamantane moiety was well tolerated with a slight loss of P2X7R inhibition activity yet significantly improved physicochemical and PK properties compared to lead benzamide 1. The fluorinated benzamide series have also provided insight into poor meta bolic stability of lead benzamide 1. Through the installation of fluorine on the adamantane bridgeheads, we have blocked the common oxidation sites of adamantane and enhanced the metabolic stability of the benzamide series. The most promising candidate of this study is trifluorinated benzamide 34 which demonstrated potent P2X7R inhibition, a strong reduction in lipophilicity, improved PK properties (particularly in metabolic stability and CYP profiling) and was effective across several polymorphs of the hP2X7R. Future studies endeavor to utilize the trifluorobenzamide 34 to test the effects of P2X7R antagonism in pre-clinical models of CNS disorders and as a suitable PET radiotracer.
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